This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

This study has been terminated.
Information provided by:
Merz Pharmaceuticals GmbH Identifier:
First received: November 27, 2008
Last updated: June 30, 2010
Last verified: June 2010
The purpose of this study is to investigate the long-term safety, tolerability and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN). In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included.

Condition Intervention Phase
Nystagmus, Congenital Nystagmus, Acquired Multiple Sclerosis Drug: Neramexane mesylate Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Long-term Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus

Resource links provided by NLM:

Further study details as provided by Merz Pharmaceuticals GmbH:

Primary Outcome Measures:
  • Long-term safety, Visual acuity [ Time Frame: Baseline, week 4, month 3, 6, 9, 12, 18, 24, 30, 36 and follow-up ]

Estimated Enrollment: 48
Study Start Date: May 2009
Intervention Details:
    Drug: Neramexane mesylate
    open-label treatment of 36 months Neramexane mesylate up to 75 mg per day

Ages Eligible for Study:   18 Years to 81 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients who has succesfully completed the lead-in study MRZ 92579-0707/1

Exclusion Criteria:

  • Occurence of any major treatment-emergent adverse event or condition during the previous protocol (MRZ 92579-0707/1)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00799942

United Kingdom
University of Leicester, Leicester Royal Infirmary, Ophthalmology Group
Leicester, United Kingdom, LE2 7LX
Sponsors and Collaborators
Merz Pharmaceuticals GmbH
  More Information Identifier: NCT00799942     History of Changes
Other Study ID Numbers: MRZ 92579-0738/1
Study First Received: November 27, 2008
Last Updated: June 30, 2010

Keywords provided by Merz Pharmaceuticals GmbH:
Nystagmus, congenital idiopathic

Additional relevant MeSH terms:
Nystagmus, Congenital
Multiple Sclerosis
Nystagmus, Pathologic
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Ocular Motility Disorders
Cranial Nerve Diseases
Eye Diseases
Infant, Newborn, Diseases processed this record on August 17, 2017